Eslovàquia - eslovac - ŠÚKL (Štátny ústav pre kontrolu liečiv)

aspen pharma trading limited, Írsko - melfalán - 44 - cytostatica

Eslovàquia - eslovac - ŠÚKL (Štátny ústav pre kontrolu liečiv)

aspen pharma trading limited, Írsko - melfalán - 44 - cytostatica

Unió Europea - eslovac - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - viacnásobný myelóm - antineoplastické činidlá - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Unió Europea - eslovac - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastické činidlá - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Eslovàquia - eslovac - ŠÚKL (Štátny ústav pre kontrolu liečiv)

zentiva k.s., Česká republika - melfalán - 44 - cytostatica

Unió Europea - eslovac - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - talidomid - viacnásobný myelóm - imunosupresíva - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

Unió Europea - eslovac - EMA (European Medicines Agency)

lipomed gmbh - talidomid - viacnásobný myelóm - imunosupresíva - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.

Unió Europea - eslovac - EMA (European Medicines Agency)

pharma mar, s.a. - plitidepsin - viacnásobný myelóm - antineoplastické činidlá, - liečba mnohopočetného myelómu.

Unió Europea - eslovac - EMA (European Medicines Agency)

pharmaand gmbh - bezvodý laktát panobinostatu - viacnásobný myelóm - antineoplastické činidlá - farydak v kombinácii s bortezomibom a dexametazónom je indikovaný na liečbu dospelých pacientov s relabovaným alebo refraktérnym mnohopočetným myelómom, ktorí dostali najmenej dve predchádzajúce vrátane bortezomibu a imunomodulačného. farydak v kombinácii s bortezomibom a dexametazónom je indikovaný na liečbu dospelých pacientov s relabovaným alebo refraktérnym mnohopočetným myelómom, ktorí dostali najmenej dve predchádzajúce vrátane bortezomibu a imunomodulačného.

Unió Europea - eslovac - EMA (European Medicines Agency)

pfizer europe ma eeig - temsirolimus - carcinoma, renal cell; lymphoma, mantle-cell - antineoplastické činidlá - obličiek-článková carcinomatorisel je uvedené, za prvé-line liečbu dospelých pacientov s pokročilým obličiek-bunky karcinómu (rcc), ktorí majú aspoň tri zo šiestich prognostické faktory rizika. plášť-článková lymphomatorisel je indikovaný na liečbu dospelých pacientov s relapsed a / alebo žiaruvzdorné plášť-bunkového lymfómu (mcl).